<DOC>
	<DOCNO>NCT02489461</DOCNO>
	<brief_summary>To evaluate follow safety efficacy parameter VM-1500 : - Decrease viral load non-quantifiable level ( &lt; 50 copies/ml ) Week 12 ( Stage I ) - Decrease viral load non-quantifiable level ( &lt; 50 copies/ml ) Week 24 ( Stage II ) - Decrease viral load 48 week treatment - Percentage subject least 10-fold ( 1 log10 ) decrease viral load Week 4 - Percentage subject decrease viral load &lt; 400 copies/ml Week 12 - Percentage subject continue receive investigational treatment Week 48 - СD4+ СD8+ cell count change 48 week study - Percentage subject develop HIV-1 resistance investigational treatment week 48 - Frequency adverse event ( AE ) different severity accord subjective complaint , physical assessment , vital sign , laboratory test , ECG - Frequency adverse event special interest , include central nervous system ( CNS ) effect - VM-1500 pharmacokinetic profile select subject</brief_summary>
	<brief_title>Efficacy , Safety Optimal Dose Selection VM-1500 Comparison Efavirenz When Added Standard-of-care Antiretroviral Therapy</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>1 . Signed Patient Information Informed Consent Form . 2 . Males female , age ≥ 18 year . 3 . HIV1 infection , confirm serologically IFA immunoblot analysis ( document HIV1 infection ) . 4 . Clinically stable HIV infection ( clinical stage 1 2 accord WHO classification ) . 5 . Indications ( Investigator 's opinion ) ART , accord WHO Summary Guideline use antiretroviral drug HIV prevention treatment ( 2013 ) . 6 . HIV1 RNA plasma level ≥ 5 000 copies/ml screening . 7 . СD4+ Тcells number &gt; 200 cells/mm3 screening . 8 . Laboratory parameter follow : White blood cell ≥ 2900/mm3 ( 2,9 x 109 cells/l ) Absolute neutrophils ≥ 1500/mm3 ( 1,5 x 109 cells/l ) Platelets ≥ 100000/mm3 ( 100 x 109 cells/l ) Hemoglobin ≥ 9.0 g/dl Total bilirubin ≤ 1.5 x ULN AST ALT≤ 2.5 x ULN Renal function GFR &gt; 60 ml/min 1 . Primary HIV1 resistance ART . Viral resistance mutation define basic mutation resistance NNRTIs , accord updated list VIH1 resistance mutation ( International AIDS society , 2013 ) , associate drug resistance genotype . 2 . History antiretroviral therapy ( ART ) , include prevention vertical transmission HIV . 3 . Acute hepatitis hepatic cirrhosis etiology ; antiHCV antibody HBsAg screening . 4 . Signs acute infection positive test result syphilis , hepatitis A , Toxoplasma gondii , cytomegalovirus , gonorrhea , Chlamydia trachomatis 30 day screen . 5 . Opportunistic infection Category C ( Centers Disease Control ( CDC ) , 2008 ) , exclude Kaposi 's sarcoma require systemic therapy . 6 . History tuberculosis localization , tuberculosis screening , accord xray examination . 7 . History malignant tumor ( except basal cell carcinoma , squamous cell carcinoma , cervical carcinoma situ , eliminate cure ≥ 5 year ago ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>